US Periodontal Disease Treatment Market

The US periodontal disease treatment market is projected to reach USD 0.94 billion by 2031 from USD 0.68 billion in 2026, growing at a CAGR of 5.5%.

The US periodontal disease treatment market is strongly driven by the growing prevalence of oral health disorders, including periodontal disease, gingivitis, and other chronic dental conditions, which continue to affect a large portion of the population. Rising cases of edentulism, especially among elderly individuals and patients with long-standing periodontal issues, are increasing the demand for advanced periodontal therapies and supporting equipment. Moreover, the emergence of innovative dental treatment procedures, such as laser-based therapies, minimally invasive surgical techniques, and digitally enabled periodontal solutions, is enhancing treatment effectiveness, reducing recovery time, and encouraging adoption among dental professionals. In addition, the expanding dental tourism market in emerging economies is intensifying global competition, prompting US manufacturers to focus on technological innovation, product differentiation, and enhanced treatment efficiency to maintain their market position.

To know about the assumptions considered for the study download the pdf brochure

Some prominent players operating in the market include Dentsply Sirona (US), Henry Schein Inc. (US), Nakanishi Inc. (Japan), and Envista (US), among others.

Leading players in the US market strengthen their competitive position through continuous innovation and strategic collaborations. Companies are increasing R&D investments to develop ergonomically advanced and technologically enhanced dental systems that enhance treatment accuracy, patient comfort, and clinical efficiency. To expand their presence across the US, market participants actively pursue partnerships and acquisitions, thereby expanding their product portfolios and gaining access to diverse dental care networks. Additionally, many firms adopt organic growth strategies, such as launching new products and obtaining approvals from regulatory bodies, including national dental health authorities. Collectively, these initiatives enhance competitiveness, address evolving demands in dental care, and foster a strong and sustainable market presence.

• In October 2024, RTI Surgical announced the acquisition of Collagen Solutions, strengthening its portfolio with the addition of a premier global supplier of engineered medical-grade collagen and xenograft tissue solutions.

• In February 2024, BIOLASE, Inc. (a subsidiary of MegaGen Implant)  announced the launch of its advanced all-tissue laser system, Waterlase iPlus Premier Edition. This latest release represents a significant enhancement to the industry-leading Waterlase iPlus platform, delivering cutting-edge innovation and setting a new benchmark for precision, versatility, and performance in modern dental care.

• In December 2023, Dentsply Sirona launched the OSSIX Agile biomaterial, a long-lasting pericardium membrane used for bone graft and tissue regeneration.

DENTSPLY SIRONA  (US)

Dentsply Sirona is a key player in the US periodontal disease treatment market. The company provides a variety of innovative dental solutions. Among these solutions, the company has a specific product line for the care of periodontal diseases. Given the advancements in technologies and, therefore, a comprehensive portfolio of products, Dentsply Sirona provides solutions for periodontal scaling, root planing, and maintenance therapy, all of which are critical to the effective management of periodontal diseases.

Dentsply Sirona will continue to play an increasingly vital role in promoting options for periodontal treatments, enhancing patient outcomes, and supporting dental professionals in achieving efficient and effective work through its robust global distribution network, strategic partnerships, and focused research and development.

INSTITUT STRAUMANN AG (SWITZERLAND)

Institut Straumann is a leader in the US periodontal disease treatment market. The company is actively involved in dental implantology and restorative dentistry within this field. It offers a range of innovative solutions, including regenerative products designed to enhance periodontal regeneration and promote healing in patients with periodontal disease. Straumann's portfolio includes biomaterials, such as bone grafts and membranes, which are essential for periodontal surgeries to restore lost bone and tissue.

HENRY SCHEIN, INC. (US)

Henry Schein is an American company that has been recognized as one of the Fortune World's Most Admired Companies. It is the world's largest distributor of healthcare products and services. The company supplies a wide range of animal health, medical, and dental products to office-based healthcare professionals. The company also offers equipment financing, practice management software, and other value-added services. Henry Schein is one of the leading players in the US periodontal disease treatment market, offering a range of products and services to help dental practitioners manage periodontal diseases. Among the world's largest distributors of dental supplies, Henry Schein provides dentists with advanced instruments for their practices, including dental lasers, scaling instruments, and other regenerative materials featured in all periodontal treatments. Additionally, the firm maintains a comprehensive portfolio of pharmaceuticals and diagnostic products that aid in the early detection and treatment of periodontal disease.

Apart from product supply, Henry Schein's focus on educating and training dental practitioners has given the company significant relevance in this market. All possible means of continuing education programs, workshops, and online resources through which a dental practitioner can acquire all information about the latest trends and best practices of treating periodontal care allow Henry Schein to become a one-stop solution that can help both general dentists and periodontists carry out effective treatment outcomes for patients suffering from periodontal disease.

MARKET RANKING

In the US periodontal disease treatment market, the competitive landscape is shaped by a mix of leading multinational corporations and prominent national suppliers. Dentsply Sirona (US) holds a leading position, driven by its broad product portfolio, extensive distribution network, and long-standing brand reputation. The company sustains its leadership through continuous product innovation and practitioner-focused marketing efforts. Another major player is Envista (US), which, although based abroad, has a significant influence on the US and international dental markets through its advanced digital dentistry solutions.

Related Reports:

US Periodontal Disease Treatment Market by Product (Equipment, Consumables), Disease (Gingivitis, Periodontitis), Treatment (Bone Grafting, Scaling, Flap Surgery, Regeneration), End User (Clinics, Private DSOs) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com